Please provide your email address to receive an email when new articles are posted on . In a randomized double blind, placebo-controlled trial with older men assigned either AndroGel 1% (transdermal ...

RALEIGH, N.C.--(BUSINESS WIRE)--Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone deficiency, today announced ...

This patent application has not been assigned to a company or institution. The following quote was obtained by the news editors from the background information supplied by the inventors: "With the ...

For women, the onset of midlife brings with it an array of distressing symptoms related to changes in hormone levels. The risk of dementia increases with age – particularly after the mid-60s – memory ...

The U.S. Food and Drug Administration today announced that it is requiring manufacturers of two prescription topical testosterone gel products, AndroGel 1% and Testim 1%, to include a boxed warning on ...

There is still considerable controversy concerning the role of androgen therapy for hypoactive sexual desire disorder in females. Clinical trials have shown that exogenous testosterone therapy ...

LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - Pharma stock news; BioSante Pharmaceuticals, Inc. BPAX reports a New Drug Application (NDA) has been accepted for filing by the U.S.